Apyx Medical (APYX) Q1 2026 earnings review
AYON Launch Drives Accelerating Growth as Breakeven Approaches
Apyx Medical has successfully reversed its top-line struggles, delivering 32% YoY revenue growth in Q1 and proving that the late-2025 launch of its AYON system was a structural turning point. The volume recovery is translating effectively to the bottom line—operating expenses remained completely flat YoY at $8.8M, allowing Adjusted EBITDA loss to shrink from $2.4M a year ago to just $0.3M today. Fueled by a breakthrough in South Korea and continued U.S. adoption of AYON, management confidently raised FY26 revenue guidance. The company is now well-positioned to ride the GLP-1 macro tailwind with a leaner cost structure.
🐂 Bull Case
The core Surgical Aesthetics segment grew 36% YoY, driven by the U.S. rollout of the AYON system and rising global demand for single-use handpieces. Operating leverage is firmly in place.
International sales surged 63% YoY to $4.4M, spearheaded by recent regulatory approval and console sales in South Korea, opening up a massive new cosmetic surgery market.
🐻 Bear Case
Despite a Q1 uptick, full-year guidance implies a severe 33% YoY contraction in OEM revenue, which will offset some of the top-line gains from the aesthetics business.
Tariff impacts that began in late 2025 remain a headwind. While geographic and product mix masked the impact this quarter, limited pricing power could cap gross margin expansion.
⚖️ Verdict: 🟢
Bullish. Management has delivered on its restructuring promises. Growth is accelerating, cash burn is practically halted, and the product portfolio is perfectly positioned for the post-GLP-1 body contouring boom.
Key Themes
AYON System Sparks U.S. Acceleration
The all-in-one AYON Body Contouring System remains the primary growth engine. Since its full commercial launch in September 2025, Surgical Aesthetics revenue growth has reversed from flat-to-negative into explosive >35% YoY expansion. Management is successfully executing its strategy to replace legacy generator sales with this higher-value ecosystem.
South Korea Unlocks International Surge
After quarters of sluggish or negative international growth, the segment reversed course violently, accelerating to 63% YoY growth ($4.4M). This was directly catalyzed by December 2025 regulatory approval in South Korea. Management accurately identifies this as a highly attractive growth vector, citing a local cosmetic surgery market projected to exceed $3.9 billion by 2031.
The GLP-1 Macro Tailwind
Management continues to position Renuvion as the 'standard of care' for treating skin laxity—a direct side effect for the estimated 15+ million Americans using GLP-1 weight loss drugs. This structural macro shift is driving higher attach rates and increased standalone procedure volumes for single-use handpieces.
OEM Growth Contradicts Dire Guidance
A notable contradiction emerged in the OEM segment. OEM revenue actually grew 13.8% in Q1 to $1.8M. However, FY26 guidance targets just $5.0M for the full year. This implies that Q1 is an anomaly, and OEM revenue will plunge to roughly $1M per quarter for the rest of the year—a steep deceleration that will drag on overall company growth.
Sequential Revenue Normalization
While YoY numbers look fantastic, revenue decelerated sequentially from $19.2M in 25Q4 to $12.5M in 26Q1. While Q4 is historically the strongest quarter driven by year-end capital equipment budgets, the steep 35% sequential drop requires monitoring to ensure AYON demand is not entirely front-loaded by early adopters.
Tariff Costs Hidden by Favorable Mix
Gross margin expanded to 63.5% from 60.1% a year ago, but this was entirely driven by segment mix (more high-margin Surgical Aesthetics, fewer low-margin OEM). Management admitted this mix benefit was partially offset by tariffs that began affecting the company in H2 2025, signaling an ongoing structural cost headwind.
Other KPIs
Stable and strictly controlled. Despite 32% top-line growth, OpEx rose by less than $100k YoY. This proves the restructuring initiatives enacted in late 2024 were structural rather than temporary, driving extreme operating leverage and pushing the company to the brink of profitability.
Down slightly from $31.7M at the end of FY25. Because cash burn has essentially been eliminated (Adj EBITDA -$0.3M), management projects current liquidity is sufficient to fund operations through 2027. Dilution risk has been removed from the immediate horizon.
Guidance
Accelerating. Raised from prior guidance of $57.5-$58.5M. The $59.5M midpoint implies 12.7% YoY growth versus FY25 ($52.8M). This signifies management's confidence that the AYON and South Korea momentum will easily overpower the planned OEM decline.
Accelerating. Raised from prior guidance of $53.0-$54.0M. The midpoint implies 20.2% YoY growth compared to FY25 ($45.3M), establishing this segment as the absolute core of Apyx's future.
Decelerating aggressively. Up slightly from prior guidance of $4.5M, but still implies a 33% collapse versus FY25 ($7.5M). Management frames this as an intentional shift of focus toward Surgical Aesthetics.
Stable. If OpEx comes in at exactly $45.0M, it would be essentially flat compared to the annualized run rate of recent quarters. This commitment to cost discipline underpins the path to generating cash.
Key Questions
South Korea Sustainability
International sales grew 63% driven by South Korea. Is this a one-time stocking event for new distributors following the December 2025 approval, or a sustainable baseline? What is the pipeline for further international regulatory approvals?
OEM Cadence
OEM revenue grew 14% to $1.8M in Q1, but full-year guidance is just $5.0M. What is driving the implied drop-off to ~$1M per quarter for the rest of the year, and how much fixed overhead is stranded by this volume decline?
AYON Utilization Trends
With the AYON base expanding rapidly, are you seeing single-use handpiece utilization rates per console tracking higher than the legacy Apyx One generators, specifically driven by the integration of liposuction capabilities?